Skip to Content

Implanted Device Controls Rheumatoid Arthritis

A nerve-stimulating electrical implant could give people a drug-free alternative to current treatments.

In early human tests, SetPoint Medical has found that an electronic implant helped reduce the symptoms of rheumatoid arthritis in six of eight patients. The company, which is based in Valencia, California, is one of many groups exploring the potential of electronic implants to treat diseases by delivering pulses to nerves that regulate organ or body functions.

bio electronic implant
Body electric: This electric implant can stimulate nerves in the body to regulate organ function.

Earlier this month, pharmaceutical giant GlaxoSmithKline, medical-device manufacturer Boston Scientific, and others invested $27 million in SetPoint. Although nerve-stimulating devices have been available for many years, GSK and academic researchers argue that the field of bioelectronic therapies is just beginning to ramp up and that in the future many conditions could be treated with electrical impulses.

external collar
Outside influence: SetPoint is developing a new implant that can be charged with an external collar, which also provides wireless communication with an iPad app to monitor and adjust treatment.

The arthritis-regulating device is implanted in the patient’s neck and wraps around the vagus nerve, a bundle of nerve fibers that communicates sensory information from internal organs and controls involuntary body functions such as heart rate and digestion. The device stimulates the nerve at regular intervals in a particular pattern that regulates the immune system, which is overactive in rheumatoid arthritis.

Brain implants have previously been used to treat movement disorders and some psychiatric conditions (see “Brain Implants Can Rest Misfiring Circuits”). Devices are also used to stimulate nerves outside the brain. An electrical device that stimulates the vagus nerve is already used to treat some cases of drug-resistant epilepsy and depression, and another is undergoing testing as a treatment for congestive heart failure. But SetPoint is covering new ground by testing peripheral-nerve stimulation as a treatment for immune disease.

“The industry is expanding rapidly,” says Kenneth Gustafson, a biomedical engineer at Case Western Reserve University in Cleveland, who is studying electrical nerve stimulation as a way to treat bladder dysfunction. The precedent set by pacemakers, deep brain implants, and other such devices enables researchers to “take that existing technology and repurpose it for all these new applications,” he says.

Researchers say the main advantage of the electrical devices over drug treatments is that they may not cause as many side effects. “Electrostimulation can be much more selective,” Gustafson says. “The targets are neural circuits that are not behaving as they should.” Drugs, on the other hand, often affect many pathways in the body.

SetPoint has been running animal and human trials using devices developed by another company to treat epilepsy. In the future, trials will use a proprietary device that is smaller and specifically engineered for the infrequent stimulation needed to treat rheumatoid arthritis. The company will soon launch another small patient study to test stimulation in patients with Crohn’s disease, an autoimmune condition that attacks the gastrointestinal system.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.